Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement on the Senate Finance Committee hearing: “Prescription Drug Affordability and Innovation: Addressing Challenges in Today’s Market: “We share the Administration’s goal of reducing drug prices.”
Featured
Industry News ASRAZENECA PHARMACEUTICALS LP: AstraZeneca provides update on GALATHEA Phase III trial for Fasenra in chronic obstructive pulmonary disease
Federal Issues UNITEDHEALTH GROUP: UnitedHealth Group Statement on Trump Administration’s Drug Policy Proposal
Latest News
Industry News ACADIA PHARMACEUTICALS INC.: ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement for the North American Development and Commercialization of Trofinetide in Rett Syndrome
Federal Issues
- U.S. DEPARTMENT OF HOMELAND SECURITY: DHS Statement on Protecting the Nation from Foreign Terrorist Entry to the United States
- PHARMACEUTICAL CARE MANAGEMENT CARE ASSOCIATION: Federal Circuit Court Unanimously Strikes Down Arkansas Mandate Restricting PBM Tools
- PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION: Congressional Budget Office Score of Medicare Point-of-Sale Rebates Undermines Drugmakers’ Signature Issue
- U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES: HHS Secretary Azar Praises FDA Approval of First Non-Opioid Treatment for Opioid Withdrawal
Industry News
ASTELLAS PHARMA US, INC: Astellas Statement on U.S. Drug Pricing
- UPPER-SMITH LABORATORIES, INC: UPSHER-SMITH EXPANDS PORTFOLIO WITH SIXTH PRODUCT LAUNCH IN 2018
- TEVA PHARMACEUTICALS USA, INC: Teva Announces Updated Indication and Vial Presentation for GRANIX® (tbo-filgrastim) Injection in United States
- ACADIA PHARMACEUTICALS INC.: ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement for the North American Development and Commercialization of Trofinetide in Rett Syndrome
- PORTOLA PHARMACEUTICALS: U.S. Centers for Medicare and Medicaid Services (CMS) Grants New Technology Add-On Payment for Portola Pharmaceuticals’ Andexxa
Innovation
- BAXTER: Baxter Announces U.S. FDA Clearance of New Spectrum IQ Infusion System
- ELI LILLY AND COMPANY: Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache
- GILEAD SCIENCES, INC: U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents
- GENENTECH, INC:Genentech Provides Update on Phase III Study Of TECENTRIQ (Atezolizumab) and COTELLIC (Cobimetinib) in People With Heavily Pre-Treated Locally Advanced or Metastatic Colorectal Cancer
Regulatory
- PFIZER: U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
- GENENTECH, INC: Genentech Announces Submission of Supplemental New Drug Application for Venclexta for People With Previously Untreated Acute Myeloid Leukemia who are Ineligible for Intensive Chemotherapy
- HALOZYME THERAPEUTICS, INC: FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
- MERCK: FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Hepatocellular Carcinoma
Alerts Sign-up